This medication is approved by the Ministry of Health, Labour, and Welfare in Japan for the treatment of type 2 diabetes, but it is not approved for obesity treatment in Japan. Medications like Wegovy (semaglutide) and Saxenda are approved for obesity treatment in Japan. Additionally, an injectable version of the same active ingredient has been approved by the U.S. FDA for obesity treatment.

This medication is sourced from authorized domestic distributors (pharmaceutical wholesalers).

Possible side effects include nausea, stomach pain, diarrhea, constipation, acute pancreatitis, and hypoglycemia symptoms such as cold sweats, dizziness, trembling, feeling faint, and weakness.

In the rare case of severe side effects, this medication will not be covered by the National Adverse Drug Reaction Relief System.

Victoza, which contains the same ingredient as Saxenda (liraglutide), is approved by the Ministry of Health, Labour, and Welfare for the treatment of type 2 diabetes. However, Saxenda is not approved in Japan for obesity treatment. Medications like Wegovy and Sanorex are approved in Japan for treating obesity. Saxenda is approved by the U.S. Food and Drug Administration (FDA) as a treatment for obesity. This medication is imported through a distributor, following the official process by under the judgment of our clinic's physicians and The Ministry of Health, Labour and Welfare.

Possible side effects include vomiting, abdominal pain, diarrhea, constipation, acute pancreatitis, and symptoms of low blood sugar (cold sweat, nausea, trembling hands and feet, dizziness, and weakness).

In the rare case of severe side effects, this medication will not be covered by the National Adverse Drug Reaction Relief System.

This medication is approved by the Ministry of Health, Labour, and Welfare for the treatment of type 2 diabetes. However, it is not approved for use in obesity treatment in Japan. Medications like Wegovy and Sanorex are approved for obesity treatment in Japan. The use of this medication for obesity treatment is not approved in other countries either, meaning the potential risks may not be fully understood. The medication is sourced from an authorized domestic distributor (pharmaceutical wholesaler).

Side effects may include urinary tract infections such as cystitis (painful urination, sensation of incomplete bladder emptying, frequent urination, excessive urination), genital infections (itching or pain in the genital area, unusual discharge), dry mouth, ketosis, loss of appetite, excessive thirst, constipation, diarrhea, and abdominal pain.

In the rare case of severe side effects, this medication will not be covered by the National Adverse Drug Reaction Relief System.

This medication is approved by the Ministry of Health, Labour, and Welfare for the treatment of obesity.

This medication is approved by the Ministry of Health, Labour, and Welfare for the treatment of type 2 diabetes. However, it is not approved for use in obesity treatment in Japan.

The medication is sourced from an authorized domestic distributor (pharmaceutical wholesaler).

Side effects may include vomiting, abdominal pain, diarrhea, constipation, acute pancreatitis, and symptoms of low blood sugar (cold sweat, nausea, trembling hands and feet, dizziness, and weakness).

In the rare case of severe side effects, this medication will not be covered by the National Adverse Drug Reaction Relief System.

This medication is approved by the Ministry of Health, Labour, and Welfare for the treatment of type 2 diabetes. However, it is not approved for obesity treatment in Japan.

The medication is sourced from an authorized domestic distributor (pharmaceutical wholesaler).

Side effects may include vomiting, abdominal pain, diarrhea, constipation, acute pancreatitis, and symptoms of low blood sugar (cold sweats, nausea, trembling hands and feet, dizziness, and weakness).

In the rare case of severe side effects, this medication will not be covered by the National Adverse Drug Reaction Relief System.